

CITATION REPORT

List of articles citing

α -synuclein misfolding and Parkinson's disease

DOI: 10.1016/j.bbadis.2011.10.002

Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 261-85.

Source: <https://exaly.com/paper-pdf/53631684/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
470	Intraneuronal β -amyloid and its interactions with proteins and subcellular organelles. 2012 , 33, 3608-16		20
469	Impact of N-terminal acetylation of β -synuclein on its random coil and lipid binding properties. 2012 , 51, 5004-13		153
468	Bioinorganic chemistry of copper coordination to alpha-synuclein: Relevance to Parkinson's disease. 2012 , 256, 2188-2201		101
467	A reduced graphene oxide based electrochemical biosensor for tyrosine detection. 2012 , 23, 335707		66
466	Microbial manipulation of the amyloid fold. 2012 , 163, 592-606		55
465	Structural basis behind the interaction of Zn^{2+} with the protein β -synuclein and the A β peptide: a comparative analysis. 2012 , 117, 334-41		40
464	Fibril-forming motifs are essential and sufficient for the fibrillization of human Tau. 2012 , 7, e38903		17
463	Loss of functional alpha-synuclein: a toxic event in Parkinson's disease?. 2012 , 2, 249-67		52
462	The role of β -synuclein in neurodegeneration [An update. 2012 , 3,		12
461	Binding of Dopamine to Alpha-Synuclein is Mediated by Specific Conformational States. 2013 , 24, 1346-54		25
460	Study of wild-type β -synuclein binding and orientation on gold nanoparticles. 2013 , 29, 4603-15		79
459	The remarkable conformational plasticity of alpha-synuclein: blessing or curse?. 2013 , 19, 368-77		67
458	Exploring the accessible conformations of N-terminal acetylated β -synuclein. 2013 , 587, 1128-38		27
457	β -Synuclein coaggregation in familial amyotrophic lateral sclerosis with SOD1 gene mutation. 2013 , 44, 1171-6		23
456	Influence of gold nanoparticles on the kinetics of β -synuclein aggregation. 2013 , 13, 6156-63		105
455	Intrinsically disordered regions of p53 family are highly diversified in evolution. 2013 , 1834, 725-38		58
454	The function of β -synuclein. 2013 , 79, 1044-66		475

453	Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies. 2013 , 125, 491-511	102
452	Potassium depolarization and raised calcium induces β synuclein aggregates. 2013 , 23, 378-92	43
451	Effects of Cu ²⁺ on aggregation behavior of poly (l-Glutamic Acid)-functionalized gold nanoparticles. 2013 , 15, 1	4
450	Raised calcium and oxidative stress cooperatively promote alpha-synuclein aggregate formation. 2013 , 62, 703-11	45
449	Molecular chaperones, β synuclein, and neurodegeneration. 2013 , 47, 552-60	39
448	On-surface aggregation of β synuclein at nanomolar concentrations results in two distinct growth mechanisms. <i>ACS Chemical Neuroscience</i> , 2013 , 4, 408-17	5-7 56
447	A decade and a half of protein intrinsic disorder: biology still waits for physics. 2013 , 22, 693-724	341
446	Glutathione metabolism and Parkinson's disease. 2013 , 62, 13-25	276
445	Differential contribution of lipoxygenase isozymes to nigrostriatal vulnerability. 2013 , 228, 73-82	15
444	A nanobody binding to non-amyloidogenic regions of the protein human lysozyme enhances partial unfolding but inhibits amyloid fibril formation. 2013 , 117, 13245-13258	33
443	Biophysical Characterization of β synuclein and Rotenone Interaction. 2013 , 3, 703-32	22
442	Biophysical characterization of β synuclein and its controversial structure. 2013 , 1, 18-39	52
441	Neurochemical profile of dementia pugilistica. 2013 , 30, 981-97	29
440	NMR Metabolomics Analysis of Parkinson's Disease. 2013 , 1, 191-209	25
439	Intrinsically disordered and aggregation prone regions underlie β aggregation in S100 proteins. 2013 , 8, e76629	14
438	Role of Intermediate States in Protein Folding and Misfolding. 2014 , 433-455	
437	Digested disorder: Quarterly intrinsic disorder digest (July-August-September, 2013). 2014 , 2, e27833	5
436	Sequestration of a β hairpin for control of β synuclein aggregation. 2014 , 53, 4227-30	74

435	Characterizing Nanoscale Morphologic and Mechanical Properties of β -Synuclein Amyloid Fibrils with Atomic Force Microscopy. 2014 , 309-322		2
434	UV-induced selective oxidation of Met5 to Met-sulfoxide leads to the formation of neurotoxic fibril-incompetent β -Synuclein oligomers. 2014 , 21, 163-74		16
433	Structure activity relationship of phenolic acid inhibitors of β -Synuclein fibril formation and toxicity. 2014 , 6, 197		78
432	Hypothesis: a role for EBV-induced molecular mimicry in Parkinson's disease. 2014 , 20, 685-94		36
431	Pitfalls associated with the use of Thioflavin-T to monitor anti-fibrillogenic activity. 2014 , 24, 3194-8		37
430	Integrating pathways of Parkinson's disease in a molecular interaction map. 2014 , 49, 88-102		178
429	Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic review. 2014 , 130, 59-72		102
428	Ageing and Parkinson's disease: why is advancing age the biggest risk factor?. 2014 , 14, 19-30		487
427	Computational approaches to understanding protein aggregation in neurodegeneration. 2014 , 6, 104-15		32
426	Curli biogenesis: order out of disorder. 2014 , 1843, 1551-8		140
425	The crowd you're in with: effects of different types of crowding agents on protein aggregation. 2014 , 1844, 346-57		66
424	β -Synuclein oligomers distinctively permeabilize complex model membranes. 2014 , 281, 2838-50		48
423	Preventing β -Synuclein aggregation: the role of the small heat-shock molecular chaperone proteins. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014 , 1842, 1830-43	6.9	61
422	Physicochemical properties of cells and their effects on intrinsically disordered proteins (IDPs). <i>Chemical Reviews</i> , 2014 , 114, 6661-714	68.1	301
421	The use of nanopore analysis for discovering drugs which bind to β -Synuclein for treatment of Parkinson's disease. 2014 , 88, 42-54		32
420	Oligomerization of Cysteine String Protein alpha mutants causing adult neuronal ceroid lipofuscinosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014 , 1842, 2136-46	6.9	22
419	Direct observation of the three regions in β -Synuclein that determine its membrane-bound behaviour. 2014 , 5, 3827		266
418	Wrecked regulation of intrinsically disordered proteins in diseases: pathogenicity of deregulated regulators. <i>Frontiers in Molecular Biosciences</i> , 2014 , 1, 6	5.6	68

417	Steuerung der β Synuclein-Aggregation durch Bindung einer β -Haarnadel. 2014 , 126, 4311-4314	5
416	Ion mobility-mass spectrometry-based screening for inhibition of β synuclein aggregation. 2015 , 21, 255-64	9
415	Identification of novel autophagic Radix Polygalae fraction by cell membrane chromatography and UHPLC-(Q)TOF-MS for degradation of neurodegenerative disease proteins. 2015 , 5, 17199	21
414	Unveiling transient protein-protein interactions that modulate inhibition of alpha-synuclein aggregation by beta-synuclein, a pre-synaptic protein that co-localizes with alpha-synuclein. 2015 , 5, 15164	39
413	Transient β hairpin formation in β synuclein monomer revealed by coarse-grained molecular dynamics simulation. 2015 , 143, 243142	49
412	Social Cognition Impairments in Mice Overexpressing Alpha-Synuclein Under the Thy1 Promoter, a Model of Pre-manifest Parkinson's Disease. 2015 , 5, 669-680	16
411	Biochemical protective effect of 1,25-dihydroxyvitamin D3 through autophagy induction in the MPTP mouse model of Parkinson's disease. 2015 , 26, 669-74	19
410	Cuminaldehyde as the Major Component of Cuminum cyminum, a Natural Aldehyde with Inhibitory Effect on Alpha-Synuclein Fibrillation and Cytotoxicity. 2015 , 80, H2336-45	49
409	Effects of Trehalose on Thermodynamic Properties of Alpha-synuclein Revealed through Synchrotron Radiation Circular Dichroism. 2015 , 5, 724-34	22
408	Opportunities for Conformation-Selective Antibodies in Amyloid-Related Diseases. 2015 , 4, 170-196	3
407	Seeking a mechanism for the toxicity of oligomeric β synuclein. 2015 , 5, 282-305	132
406	Direct and/or Indirect Roles for SUMO in Modulating Alpha-Synuclein Toxicity. 2015 , 5, 1697-716	24
405	Fairy "tails": flexibility and function of intrinsically disordered extensions in the photosynthetic world. <i>Frontiers in Molecular Biosciences</i> , 2015 , 2, 23	5.6 20
404	The N-terminal residues 43 to 60 form the interface for dopamine mediated β synuclein dimerisation. 2015 , 10, e0116497	7
403	Did β Synuclein and Glucocerebrosidase Coevolve? Implications for Parkinson's Disease. 2015 , 10, e0133863	6
402	The N Terminus of β Synuclein Forms Cu(II)-Bridged Oligomers. 2015 , 21, 7111-8	16
401	Mechanisms of alpha-synuclein action on neurotransmission: cell-autonomous and non-cell autonomous role. 2015 , 5, 865-92	29
400	Formation of covalent di-tyrosine dimers in recombinant β synuclein. 2015 , 3, e1071302	13

399	ELECTRONIC ANALOGY TO SIMULATE AND PREDICT THE DYNAMICS OF CELLULAR MECHANISM OF PARKINSON'S DISEASE STIMULATED BY ENVIRONMENTAL FACTORS. 2015 , 27, 1550051		
398	Review: Modulating the unfolded protein response to prevent neurodegeneration and enhance memory. 2015 , 41, 414-27		56
397	Prospects for polymer therapeutics in Parkinson's disease and other neurodegenerative disorders. 2015 , 44, 79-112		21
396	Electrochemistry of nonconjugated proteins and glycoproteins. Toward sensors for biomedicine and glycomics. <i>Chemical Reviews</i> , 2015 , 115, 2045-108	68.1	223
395	Dimerization propensities of Synucleins are not predictive for Synuclein aggregation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015 , 1852, 1658-64	6.9	13
394	Nascent β -Hairpin Formation of a Natively Unfolded Peptide Reveals the Role of Hydrophobic Contacts. 2015 , 109, 630-8		6
393	Cholesterol - A putative endogenous contributor towards Parkinson's disease. 2015 , 90, 125-33		43
392	β Synuclein interactions with phospholipid model membranes: Key roles for electrostatic interactions and lipid-bilayer structure. 2015 , 1848, 2002-12		33
391	Protein Misfolding in Lipid-Mimetic Environments. 2015 , 855, 33-66		10
390	The effect of mesoporous silica nanoparticle surface chemistry and concentration on the β Synuclein fibrillation. 2015 , 5, 60966-60974		24
389	Intrastriatal injection of pre-formed mouse β Synuclein fibrils into rats triggers β Synuclein pathology and bilateral nigrostriatal degeneration. 2015 , 82, 185-199		211
388	Oligomers of Parkinson's Disease-Related β Synuclein Mutants Have Similar Structures but Distinctive Membrane Permeabilization Properties. 2015 , 54, 3142-50		34
387	Urocortin--from Parkinson's disease to the skeleton. 2015 , 60, 130-8		3
386	Direct Detection of β Synuclein Dimerization Dynamics: Single-Molecule Fluorescence Analysis. 2015 , 108, 2038-47		36
385	Parkinson's Disease. 2015 , 223-251		
384	Definition of a molecular pathway mediating β Synuclein neurotoxicity. 2015 , 35, 5221-32		128
383	Electronic Simulation of Neuronal Degeneration in Parkinson Disease. 2015 , 40, 97-102		
382	Characterization of Protein Structural Changes in Living Cells Using Time-Lapsed FTIR Imaging. 2015 , 87, 6025-31		30

381	Bacterial amyloid formation: structural insights into curli biogenesis. 2015 , 23, 693-706		111
380	Control of protein orientation on gold nanoparticles. 2015 , 119, 21035-21043		59
379	Conformational dynamics of β -synuclein: insights from mass spectrometry. 2015 , 140, 3070-81		29
378	Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways. 2015 , 81, 76-92		47
377	Therapeutic strategies in Parkinson's disease: what we have learned from animal models. 2015 , 1338, 16-37		24
376	Purification of β -synuclein from human brain reveals an instability of endogenous multimers as the protein approaches purity. 2015 , 54, 279-92		56
375	Proteins without unique 3D structures: biotechnological applications of intrinsically unstable/disordered proteins. 2015 , 10, 356-66		19
374	Biosensors in Health Care: The Milestones Achieved in Their Development towards Lab-on-Chip-Analysis. 2016 , 2016, 3130469		90
373	Abnormal Salivary Total and Oligomeric Alpha-Synuclein in Parkinson's Disease. 2016 , 11, e0151156		59
372	Combination therapies: The next logical Step for the treatment of synucleinopathies?. <i>Movement Disorders</i> , 2016 , 31, 225-34	7	39
371	Chapter 14 Deep Brain Stimulation for Memory Dysfunction. 2016 , 257-274		
370	The Parkinson Disease gene SNCA: Evolutionary and structural insights with pathological implication. 2016 , 6, 24475		66
369	Metallothioneins in Prion- and Amyloid-Related Diseases. 2016 , 51, 637-56		16
368	X-ray Crystallographic Structure of Oligomers Formed by a Toxic β -Hairpin Derived from β -Synuclein: Trimers and Higher-Order Oligomers. 2016 , 138, 4458-67		39
367	Protein aggregation and ER stress. 2016 , 1648, 658-666		64
366	Potential applications of stress solutes from extremophiles in protein folding diseases and healthcare. 2016 , 20, 251-9		14
365	Temperature, surface morphology and biochemical cues: A combined approach to influence the molecular conformation of Alpha-synuclein. 2016 , 158, 64-68		2
364	UBC9-Mediated Sumoylation Favorably Impacts Cardiac Function in Compromised Hearts. 2016 , 118, 1894-905		37

363	In vitro neurotoxic hazard characterisation of dinitrophenolic herbicides. 2016 , 252, 62-9	9
362	Implantable amyloid hydrogels for promoting stem cell differentiation to neurons. 2016 , 8, e304-e304	50
361	Amorphous protein aggregation monitored using fluorescence self-quenching. 2016 , 590, 3501-3509	7
360	Neighboring amide participation in the Fenton oxidation of a sulfide to sulfoxide, vinyl sulfide and ketone relevant to oxidation of methionine thioether side chains in peptides. 2016 , 72, 7770-7789	1
359	Environmental and genetic factors support the dissociation between β synuclein aggregation and toxicity. 2016 , 113, E6506-E6515	62
358	The Impact of N-terminal Acetylation of β synuclein on Phospholipid Membrane Binding and Fibril Structure. 2016 , 291, 21110-21122	58
357	Neurodegenerative and neurological disorders by small inhaled particles. 2016 , 56, 94-106	175
356	Opposite Structural Effects of Epigallocatechin-3-gallate and Dopamine Binding to β synuclein. 2016 , 88, 8468-75	44
355	Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies. 2016 , 139 Suppl 1, 240-255	95
354	Review: Sporadic Parkinson's disease: development and distribution of β synuclein pathology. 2016 , 42, 33-50	232
353	The effect of yeast <i>Saccharomyces cerevisiae</i> red pigment on the expression of cloned human β synuclein. 2016 , 10, 264-276	1
352	Trifluoroethanol modulates β synuclein amyloid-like aggregate formation, stability and dissolution. <i>Biophysical Chemistry</i> , 2016 , 216, 23-30	3-5 6
351	Alpha-synuclein aggregates are excluded from calbindin-D28k-positive neurons in dementia with Lewy bodies and a unilateral rotenone mouse model. 2016 , 77, 65-75	14
350	Functionally different β synuclein inclusions yield insight into Parkinson's disease pathology. 2016 , 6, 23116	26
349	Efficient and biologically relevant consensus strategy for Parkinson's disease gene prioritization. 2016 , 9, 12	15
348	L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2016 , 1860, 1989-97	4 20
347	Probing the quaternary structure of metal-bridged peptide oligomers. 2016 , 158, 30-34	7
346	Advances in Mid-Infrared Spectroscopy for Chemical Analysis. 2016 , 9, 45-68	131

345	Understanding the dynamics of monomeric, dimeric, and tetrameric β synuclein structures in water. 2016 , 6, 666-86		10
344	Mesenchymal Stem Cells Inhibit Transmission of β synuclein by Modulating Clathrin-Mediated Endocytosis in a Parkinsonian Model. 2016 , 14, 835-849		50
343	β -Synuclein strains and the variable pathologies of synucleinopathies. 2016 , 139 Suppl 1, 256-274		58
342	A hyperbranched dopamine-containing PEG-based polymer for the inhibition of β synuclein fibrillation. 2016 , 469, 830-5		19
341	Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting β synuclein abnormalities in the substantia nigra. 2016 , 243, 7-21		56
340	Phase transitions and structure analysis in wild-type, A30P, E46K, and A53T mutants of β synuclein. 2016 , 45, 355-64		8
339	Pseudocatalytic Antiaggregation Activity of Antibodies: Immunoglobulins can Influence β synuclein Aggregation at Substoichiometric Concentrations. 2016 , 53, 1949-1958		9
338	A natural product inhibits the initiation of β synuclein aggregation and suppresses its toxicity. 2017 , 114, E1009-E1017		177
337	The chaperonin CCT inhibits assembly of β synuclein amyloid fibrils by a specific, conformation-dependent interaction. 2017 , 7, 40859		33
336	Distinct Mechanisms Determine β synuclein Fibril Morphology during Growth and Maturation. <i>ACS Chemical Neuroscience</i> , 2017 , 8, 538-547	5-7	31
335	Familial Mutations May Switch Conformational Preferences in β synuclein Fibrils. <i>ACS Chemical Neuroscience</i> , 2017 , 8, 837-849	5-7	25
334	Effects of Intrinsic and Extrinsic Factors on Aggregation of Physiologically Important Intrinsically Disordered Proteins. 2017 , 329, 145-185		14
333	Human Neural Progenitor Transplantation Rescues Behavior and Reduces β synuclein in a Transgenic Model of Dementia with Lewy Bodies. 2017 , 6, 1477-1490		10
332	Polyphenols in combination with β -cyclodextrin can inhibit and disaggregate β synuclein amyloids under cell mimicking conditions: A promising therapeutic alternative. 2017 , 1865, 589-603		37
331	Calcipotriol inhibits β synuclein aggregation in SH-SY5Y neuroblastoma cells by a Calbindin-D28k-dependent mechanism. 2017 , 141, 263-274		20
330	Neuroprotective Effect of Ayurvedic Preparations and Natural Products on Parkinson's Disease. 2017 , 91-105		2
329	Parkinson's disease. 2017 , 157-174		2
328	Pressure effects on β synuclein amyloid fibrils: An experimental investigation on their dissociation and reversible nature. 2017 , 627, 46-55		10

327	Amyotrophic lateral sclerosis-like superoxide dismutase 1 proteinopathy is associated with neuronal loss in Parkinson's disease brain. 2017 , 134, 113-127	56
326	A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing β Synuclein. 2017 , 14, 1107-1119	34
325	Parkinson's disease; the hibernating spore hypothesis. 2017 , 104, 48-53	10
324	β Synuclein binds to the ER-mitochondria tethering protein VAPB to disrupt Ca homeostasis and mitochondrial ATP production. 2017 , 134, 129-149	167
323	Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease. 2017 , 43, 604-620	38
322	β Synuclein Oligomers: A Study in Diversity. 2017 , 57, 699-723	12
321	Dimerization of Tyr136Cys alpha-synuclein prevents amyloid transformation of wild type alpha-synuclein. 2017 , 96, 35-43	13
320	C-Terminal Truncated β Synuclein Fibrils Contain Strongly Twisted β -Sheets. 2017 , 139, 15392-15400	57
319	Alpha-synuclein, epigenetics, mitochondria, metabolism, calcium traffic, & circadian dysfunction in Parkinson's disease. An integrated strategy for management. 2017 , 40, 149-167	37
318	The roles of intrinsic disorder-based liquid-liquid phase transitions in the "Dr. Jekyll-Mr. Hyde" behavior of proteins involved in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. 2017 , 13, 2115-2162	35
317	Modification of C Terminus Provides New Insights into the Mechanism of β Synuclein Aggregation. 2017 , 113, 2182-2191	37
316	A pH-dependent switch promotes β -synuclein fibril formation via glutamate residues. 2017 , 292, 16368-16379	26
315	Metal chelator EGCG attenuates Fe(III)-induced conformational transition of β Synuclein and protects AS-PC12 cells against Fe(III)-induced death. 2017 , 143, 136-146	26
314	Localization of β Synuclein in the Rat Brain and Its Relationship with Dopaminergic Structures. 2017 , 47, 1147-1152	
313	Copper(II) Binding Sites in N-Terminally Acetylated β Synuclein: A Theoretical Rationalization. 2017 , 121, 5711-5719	12
312	Single-cell analysis using Fourier transform infrared microspectroscopy. 2017 , 52, 560-587	32
311	The effect of β Synuclein on gliosis and IL-1 β TNF α IFN γ TGF β expression in murine brain. 2017 , 69, 242-251	16
310	β Synuclein aggregation and its modulation. 2017 , 100, 37-54	72

309	Hederagenin and Hederin promote degradation of proteins in neurodegenerative diseases and improve motor deficits in MPTP-mice. 2017 , 115, 25-44		35
308	Unraveling the Neurobiology of Sleep and Sleep Disorders Using Drosophila. 2017 , 121, 253-285		7
307	Neurodegeneration and RNA-binding proteins. 2017 , 8, e1394		17
306	Reconsidering the role of glial cells in chronic stress-induced dopaminergic neurons loss within the substantia nigra? Friend or foe?. 2017 , 60, 117-125		17
305	First-in-human assessment of PRX002, an anti- β -synuclein monoclonal antibody, in healthy volunteers. <i>Movement Disorders</i> , 2017 , 32, 211-218	7	140
304	The effects of β -synuclein oligomers on neurogenesis in the hippocampus and the behavior of aged mice. 2017 , 11, 282-289		4
303	Effects of Commonly Used Pesticides in China on the Mitochondria and Ubiquitin-Proteasome System in Parkinson's Disease. 2017 , 18,		25
302	β -Amyloid and the Pathomechanisms of Alzheimer's Disease: A Comprehensive View. 2017 , 22,		62
301	Neurodegenerative Disease Related Proteins Have Negative Effects on SNARE-Mediated Membrane Fusion in Pathological Confirmation. 2017 , 10, 66		17
300	Synuclein misfolding as a therapeutic target. 2017 , 21-47		
299	Glycosylated amyloid-like proteins in the structural extracellular polymers of aerobic granular sludge enriched with ammonium-oxidizing bacteria. 2018 , 7, e00616		33
298	Synergistic Amyloid Switch Triggered by Early Heterotypic Oligomerization of Intrinsically Disordered β -Synuclein and Tau. 2018 , 430, 2508-2520		14
297	Exploring the role of post-translational modifications in regulating β -synuclein interactions by studying the effects of phosphorylation on nanobody binding. 2018 , 27, 1262-1274		18
296	High-speed atomic force microscopy reveals structural dynamics of β -synuclein monomers and dimers. 2018 , 148, 123322		40
295	The fold preference and thermodynamic stability of β -synuclein fibrils is encoded in the non-amyloid- β component region. 2018 , 20, 4502-4512		11
294	Photophysics of diphenyl-pyrazole compounds in solutions and β -synuclein aggregates. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2018 , 1862, 800-807	4	8
293	A Systematic DFT Study of Some Plausible Zn(II) and Al(III) Interaction Sites in N-Terminally Acetylated β -Synuclein. 2018 , 122, 690-699		7
292	DOR agonist (SNC-80) exhibits anti-parkinsonian effect via downregulating UPR/oxidative stress signals and inflammatory response in vivo. 2018 , 678, 29-36		8

291	Early events in copper-ion catalyzed oxidation of β -Synuclein. 2018 , 121, 38-50		21
290	β -Synuclein strains and seeding in Parkinson's disease, incidental Lewy body disease, dementia with Lewy bodies and multiple system atrophy: similarities and differences. 2018 , 373, 195-212		61
289	Pulsed Hydrogen-Deuterium Exchange Illuminates the Aggregation Kinetics of β -Synuclein, the Causative Agent for Parkinson's Disease. <i>ACS Chemical Neuroscience</i> , 2018 , 9, 1469-1476	5-7	12
288	A routinely used protein staining dye acts as an inhibitor of wild type and mutant alpha-synuclein aggregation and modulator of neurotoxicity. 2018 , 143, 1174-1184		10
287	Dexamethasone Inhibits Copper-Induced Alpha-Synuclein Aggregation by a Metallothionein-Dependent Mechanism. 2018 , 33, 229-238		8
286	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. 2018 , 19, 244-328		148
285	Role of Sporadic Parkinson Disease Associated Mutations A18T and A29S in Enhanced β -Synuclein Fibrillation and Cytotoxicity. <i>ACS Chemical Neuroscience</i> , 2018 , 9, 230-240	5-7	10
284	Nucleic acid aptamers for neurodegenerative diseases. 2018 , 145, 73-83		30
283	Chem/bio sensing with non-classical light and integrated photonics. 2018 , 143, 593-605		11
282	Serum titers of autoantibodies against β -Synuclein and tau in child- and adulthood. 2018 , 315, 33-39		10
281	The Effects of Fibrillar Forms of β -Synuclein Protein on Neurogenesis in the Hippocampus, Dopaminergic Neurons of the Substantia Nigra, and the Behavior of Ageing Mice. 2018 , 12, 359-365		2
280	Vibrational Circular Dichroism Sheds New Light on the Competitive Effects of Crowding and β -Synuclein on the Fibrillation Process of β -Synuclein. 2018 , 57, 5989-5995		10
279	Targeting the Intrinsically Disordered Proteome Using Small-Molecule Ligands. 2018 , 611, 703-734		9
278	Polyion Complex Micelles for Protein Delivery. 2018 , 71, 768		26
277	Curcumin Effectively Rescued Parkinson's Disease-Like Phenotypes in a Novel Model with dUCH Knockdown. 2018 , 2018, 2038267		32
276	Toll-Like Receptor 2 Signaling and Current Approaches for Therapeutic Modulation in Synucleinopathies. 2018 , 9, 417		26
275	Ganglioside lipids accelerate β -Synuclein amyloid formation. 2018 , 1866, 1062-1062		35
274	Role of Ionizing Radiation in Neurodegenerative Diseases. 2018 , 10, 134		25

273	Sir-2.1 mediated attenuation of β synuclein expression by Alaskan bog blueberry polyphenols in a transgenic model of <i>Caenorhabditis elegans</i> . 2018 , 8, 10216		12
272	Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology. 2018 , 19,		37
271	Co-aggregation of pro-inflammatory S100A9 with β synuclein in Parkinson's disease: ex vivo and in vitro studies. 2018 , 15, 172		29
270	Mitochondrial dysfunction in protein conformational disorders. <i>Journal of Genetics</i> , 2018 , 97, 703-713	1.2	1
269	Parkinson's Disease and Other Synucleinopathies. 2018 , 117-143		
268	Pathways to neurodegeneration: lessons learnt from unbiased genetic screens in <i>Drosophila</i> . <i>Journal of Genetics</i> , 2018 , 97, 773-781	1.2	4
267	Investigation of β synuclein Amyloid Fibrils Using the Fluorescent Probe Thioflavin T. 2018 , 19,		23
266	In Vitro Approaches for Studying Amyloids and Neurotoxicity. 2018 , 1		
265	Alternative Splicing of Alpha- and Beta-Synuclein Genes Plays Differential Roles in Synucleinopathies. 2018 , 9,		15
264	Is Lewy pathology in the human nervous system chiefly an indicator of neuronal protection or of toxicity?. 2018 , 373, 149-160		25
263	Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti- β synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. 2018 , 75, 1206-1214		144
262	Dynamic Properties of Human β synuclein Related to Propensity to Amyloid Fibril Formation. 2019 , 431, 3229-3245		8
261	Magnesium Is a Key Player in Neuronal Maturation and Neuropathology. 2019 , 20,		32
260	Alpha-synuclein structure and Parkinson's disease - lessons and emerging principles. 2019 , 14, 29		135
259	The Gut-Brain Axis in Neurodegenerative Diseases and Relevance of the Canine Model: A Review. 2019 , 11, 130		39
258	Ginkgolic acid promotes autophagy-dependent clearance of intracellular alpha-synuclein aggregates. 2019 , 101, 103416		17
257	Complex of EGCG with Cu(II) Suppresses Amyloid Aggregation and Cu(II)-Induced Cytotoxicity of β synuclein. 2019 , 24,		19
256	Probing the Basis of β synuclein Aggregation by Comparing Simulations to Single-Molecule Experiments. 2019 , 117, 1125-1135		9

255	Metal coordination and peripheral substitution modulate the activity of cyclic tetrapyrroles on β aggregation: a structural and cell-based study. 2019 , 24, 1269-1278	0
254	Natural compound safranal driven inhibition and dis-aggregation of β synuclein fibrils. 2019 , 141, 585-595	15
253	Triphala inhibits alpha-synuclein fibrillization and their interaction study by NMR provides insights into the self-association of the protein.. 2019 , 9, 28470-28477	6
252	Surface-engineered multimodal magnetic nanoparticles to manage CNS diseases. 2019 , 24, 873-882	42
251	Efficient Detection of Early Events of β synuclein Aggregation Using a Cysteine Specific Hybrid Scaffold. 2019 , 58, 1109-1119	8
250	Mitochondrial-membrane association of β synuclein: Pros and cons in consequence of Parkinson's disease pathophysiology. 2019 , 16, 100423	1
249	Sleep, Aging, and Cellular Health: Aged-Related Changes in Sleep and Protein Homeostasis Converge in Neurodegenerative Diseases. 2019 , 11, 140	10
248	Visual discrimination impairment after experimental stroke is associated with disturbances in the polarization of the astrocytic aquaporin-4 and increased accumulation of neurotoxic proteins. 2019 , 318, 232-243	11
247	The interaction of several herbal extracts with β synuclein: Fibril formation and surface plasmon resonance analysis. 2019 , 14, e0217801	8
246	Effects of in vivo conditions on amyloid aggregation. 2019 , 48, 3946-3996	86
245	Spreading of β synuclein and Tau: A Systematic Comparison of the Mechanisms Involved. 2019 , 12, 107	53
244	The role of neurofilament aggregation in neurodegeneration: lessons from rare inherited neurological disorders. 2019 , 14, 19	34
243	In-vitro and in-silico investigation of protective mechanisms of crocin against E46K β synuclein amyloid formation. 2019 , 46, 4279-4292	6
242	Conformational ensemble of native β synuclein in solution as determined by short-distance crosslinking constraint-guided discrete molecular dynamics simulations. 2019 , 15, e1006859	36
241	β synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis. 2019 , 1867, 890-908	93
240	Lipopolysaccharide from Gut Microbiota Modulates β synuclein Aggregation and Alters Its Biological Function. <i>ACS Chemical Neuroscience</i> , 2019 , 10, 2229-2236	5-7 44
239	Reprint of "Ganglioside lipids accelerate β synuclein amyloid formation". 2019 , 1867, 508-518	3
238	β synuclein-Confocal Nanoscanning (ASYN-CONA), a Bead-Based Assay for Detecting Early-Stage β synuclein Aggregation. 2019 , 91, 5582-5590	6

237	Differential Aggregation and Phosphorylation of Alpha Synuclein in Membrane Compartments Associated With Parkinson Disease. 2019 , 13, 382	22
236	Parkinson's disease: Mechanisms, translational models and management strategies. 2019 , 226, 77-90	147
235	Alpha-Synuclein in Skin Nerve Fibers as a Biomarker for Alpha-Synucleinopathies. 2019 , 15, 135-142	21
234	βSynuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease. 2019 , 138, 1-21	60
233	The primary neuronal cells are more resistant than PC12 cells to βSynuclein toxic aggregates. 2019 , 701, 38-47	6
232	Extraction, recovery and characterization of structural extracellular polymeric substances from anammox granular sludge. 2019 , 236, 649-656	41
231	Dopamine Cytotoxicity on SH-SY5Y Cells: Involvement of βSynuclein and Relevance in the Neurodegeneration of Sporadic Parkinson's Disease. 2019 , 35, 898-907	14
230	Effect of superparamagnetic nanoparticles coated with various electric charges on βSynuclein and βAmyloid proteins fibrillation process. 2019 , 14, 799-808	13
229	Methionine oxidation in βSynuclein inhibits its propensity for ordered secondary structure. 2019 , 294, 5657-5665	15
228	Effects of βSynuclein Monomers Administration in the Gigantocellular Reticular Nucleus on Neurotransmission in Mouse Model. 2019 , 44, 968-977	0
227	Vitamin K1 As A Potential Molecule For Reducing Single-Walled Carbon Nanotubes-Stimulated βSynuclein Structural Changes And Cytotoxicity. 2019 , 14, 8433-8444	10
226	Computational insights into lipid assisted peptide misfolding and aggregation in neurodegeneration. 2019 , 21, 22679-22694	9
225	βSynuclein Penetrates Mucin Hydrogels Despite Its Mucoadhesive Properties. 2019 , 20, 4332-4344	10
224	Reducing effect of insulin resistance on alpha-synuclein gene expression in skeletal muscle. 2019 , 11, 99	4
223	Combining molecular dynamics simulations and experimental analyses in protein misfolding. <i>Advances in Protein Chemistry and Structural Biology</i> , 2019 , 118, 33-110	5-3 6
222	Alpha-synuclein is highly prone to distribution in the hippocampus and midbrain in tree shrews, and its fibrils seed Lewy body-like pathology in primary neurons. 2019 , 116, 37-45	4
221	Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases. 2019 , 151, 397-416	18
220	Heterogeneity in gut microbiota drive polyphenol metabolism that influences βSynuclein misfolding and toxicity. 2019 , 64, 170-181	37

219	Living in Promiscuity: The Multiple Partners of Alpha-Synuclein at the Synapse in Physiology and Pathology. 2019 , 20,		28
218	Quantification of Protein Aggregates Using Bimolecular Fluorescence Complementation. 2019 , 1873, 183-193		
217	Novel Alpha-Synuclein Oligomers Formed with the Aminochrome-Glutathione Conjugate Are Not Neurotoxic. 2019 , 35, 432-440		12
216	Disruptive membrane interactions of alpha-synuclein aggregates. 2019 , 1867, 468-482		33
215	Modulating β synuclein fibril formation using DNA tetrahedron nanostructures. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2019 , 1863, 73-81	4	2
214	GBA1 mutations: Prospects for exosomal biomarkers in β synuclein pathologies. 2020 , 129, 35-46		8
213	Molecular characterization of an aggregation-prone variant of alpha-synuclein used to model synucleinopathies. 2020 , 1868, 140298		5
212	Recent Progress in Autocatalytic Ceria Nanoparticles-Based Translational Research on Brain Diseases. 2020 , 3, 1043-1062		14
211	Aggregation of biologically important peptides and proteins: inhibition or acceleration depending on protein and metal ion concentrations.. 2019 , 10, 215-227		21
210	Prions and Prion-like assemblies in neurodegeneration and immunity: The emergence of universal mechanisms across health and disease. 2020 , 99, 115-130		10
209	Neuroprotective function of Omi to β synuclein-induced neurotoxicity. 2020 , 136, 104706		3
208	Interactions between Soluble Species of β Amyloid and β Synuclein Promote Oligomerization while Inhibiting Fibrillization. 2020 , 59, 425-435		5
207	Therapeutic implications of circadian clocks in neurodegenerative diseases. 2020 , 98, 1095-1113		3
206	Inhibitory effect of Euphorbia tannins on β synuclein aggregation in aqueous solutions. 2020 , 299, 112112		3
205	Activation of the CARD8 Inflammasome Requires a Disordered Region. 2020 , 33, 108264		16
204	Mechanisms of NLRP3 priming in inflammaging and age related diseases. 2020 , 55, 15-25		18
203	Brain Selective Estrogen Treatment Protects Dopaminergic Neurons and Preserves Behavioral Function in MPTP-induced Mouse Model of Parkinson's Disease. 2021 , 16, 667-678		5
202	Exploring the molecular approach of COX and LOX in Alzheimer's and Parkinson's disorder. 2020 , 47, 9895-9912		8

201	Alpha-Synuclein-Nanoparticle Interactions: Understanding, Controlling and Exploiting Conformational Plasticity. 2020 , 25,		2
200	The hot sites of β synuclein in amyloid fibril formation. 2020 , 10, 12175		2
199	Alleviating toxic β synuclein accumulation by membrane depolarization: evidence from an in vitro model of Parkinson's disease. 2020 , 13, 108		2
198	β synuclein in Parkinson's Disease: Does a Prion-Like Mechanism of Propagation from Periphery to the Brain Play a Role?. 2021 , 27, 367-387		3
197	Proteotoxicity and Neurodegenerative Diseases. 2020 , 21,		13
196	Identification of potential urine biomarkers in idiopathic parkinson's disease using NMR. <i>Clinica Chimica Acta</i> , 2020 , 510, 442-449	6.2	7
195	Comprehensive Structural and Thermodynamic Analysis of Prefibrillar WT β synuclein and Its G51D, E46K, and A53T Mutants by a Combination of Small-Angle X-ray Scattering and Variational Bayesian Weighting. 2020 , 60, 5265-5281		1
194	Relevance of Electrostatic Charges in Compactness, Aggregation, and Phase Separation of Intrinsically Disordered Proteins. 2020 , 21,		20
193	Anomalous Salt Dependence Reveals an Interplay of Attractive and Repulsive Electrostatic Interactions in β synuclein Fibril Formation. 2020 , 1,		8
192	Investigating the Convergent Mechanisms between Major Depressive Disorder and Parkinson's Disease. 2021 , 6, 47-61		2
191	VDAC1 at the Intersection of Cell Metabolism, Apoptosis, and Diseases. 2020 , 10,		34
190	Dynamic molecular exchange and conformational transitions of alpha-synuclein at the nano-bio interface. 2020 , 154, 206-216		6
189	Direct Identification of Amyloid Peptide Fragments in Human β synuclein Based on Consecutive Hydrophobic Amino Acids. <i>ACS Omega</i> , 2020 , 5, 11677-11686	3.9	1
188	DIBMA nanodiscs keep β synuclein folded. 2020 , 1862, 183314		10
187	Nanobodies derived from Camelids represent versatile biomolecules for biomedical applications. 2020 , 8, 3559-3573		12
186	Rosmarinic acid restrains protein glycation and aggregation in human serum albumin: Multi spectroscopic and microscopic insight - Possible Therapeutics Targeting Diseases. 2020 , 161, 187-193		19
185	Recent Trends in Chiroptical Spectroscopy: Theory and Applications of Vibrational Circular Dichroism and Raman Optical Activity. 2020 , 85, 561-575		36
184	Protein folding: how, why, and beyond. 2020 , 3-22		

183	In silico drug repositioning of FDA-approved drugs to predict new inhibitors for alpha-synuclein aggregation. 2020 , 88, 107308	1
182	Multitarget Therapeutic Strategies for Alzheimer's Disease: Review on Emerging Target Combinations. 2020 , 2020, 5120230	34
181	Gut microbiota differences between healthy older adults and individuals with Parkinson's disease: A systematic review. 2020 , 112, 227-241	32
180	Methods for detecting toxic β synuclein species as a biomarker for Parkinson's disease. 2020 , 57, 291-307	6
179	Solution NMR insights into dynamic supramolecular assemblies of disordered amyloidogenic proteins. 2020 , 683, 108304	4
178	Naturally occurring cinnamic acid derivatives prevent amyloid transformation of alpha-synuclein. 2020 , 170, 128-139	15
177	Discerning Dynamic Signatures of Membrane-Bound β synuclein Using Site-Specific Fluorescence Depolarization Kinetics. 2020 , 124, 708-717	9
176	The Non-amyloidal Component Region of β synuclein Is Important for β synuclein Transport Within Axons. 2019 , 13, 540	7
175	Interaction with zinc oxide nanoparticle kinetically traps β synuclein fibrillation into off-pathway non-toxic intermediates. 2020 , 150, 68-79	6
174	Alpha-synuclein fragments trigger distinct aggregation pathways. 2020 , 11, 84	10
173	S-Nitrosylation of G protein-coupled receptor kinase 6 and Casein kinase 2 alpha modulates their kinase activity toward alpha-synuclein phosphorylation in an animal model of Parkinson's disease. 2020 , 15, e0232019	4
172	Polymorphic β synuclein Strains Modified by Dopamine and Docosahexaenoic Acid Interact Differentially with Tau Protein. 2020 , 57, 2741-2765	12
171	Advances in modelling alpha-synuclein-induced Parkinson's diseases in rodents: Virus-based models versus inoculation of exogenous preformed toxic species. 2020 , 338, 108685	8
170	The function of bacterial HtrA is evolutionally conserved in mammalian HtrA2/Omi. 2020 , 10, 5284	4
169	Using NMR spectroscopy to investigate the role played by copper in prion diseases. 2020 , 41, 2389-2406	6
168	Molecular characteristics of porcine alpha-synuclein splicing variants. 2021 , 180, 121-133	1
167	β synuclein abnormalities trigger focal tau pathology, spreading to various brain areas in Parkinson disease. 2021 , 157, 727-751	1
166	Proteomic Complexity in Parkinson's Disease: A Redox Signaling Perspective of the Pathophysiology and Progression. 2021 , 453, 287-300	3

165	The contribution of gut microbiota in the pathogenesis of Parkinson's disease. 2021 , 123-141		
164	Adeno-Associated Virus Expression of β -Synuclein as a Tool to Model Parkinson's Disease: Current Understanding and Knowledge Gaps. 2021 , 12, 1120-1137		1
163	Turmeric products in Parkinson's disease treatment. 2021 , 73-87		
162	Absence of Uptake and Prion-Like Spreading of Alpha-Synuclein and Tau After Intravitreal Injection of Preformed Fibrils. 2020 , 12, 614587		3
161	Linking aging and animal models to neurodegeneration. 2021 , 539-552		
160	Modification of insulin amyloid aggregation by Zr phthalocyanines functionalized with dehydroacetic acid derivatives. 2021 , 16, e0243904		3
159	Parkinson's disease. 2021 , 1-171		1
158	[Changes in the mitochondrial subproteome of mouse brain Rpn13-binding proteins induced by the neurotoxin MPTP and the neuroprotector isatin]. 2021 , 67, 51-65		1
157	Animal models of Parkinson's review. 2021 ,		
156	Development of an β -Synuclein knockdown peptide and evaluation of its efficacy in Parkinson's disease models. 2021 , 4, 232		5
155	GBA Mutations Influence the Release and Pathological Effects of Small Extracellular Vesicles from Fibroblasts of Patients with Parkinson's Disease. 2021 , 22,		6
154	Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies. <i>Cells</i> , 2021 , 10,	7.9	20
153	Protective mechanism of Syringic acid in an experimental model of Parkinson's disease. 2021 , 36, 1003-1014		3
152	Preanalytical Stability of CSF Total and Oligomeric Alpha-Synuclein. 2021 , 13, 638718		2
151	Conformational Dynamics of β -Synuclein during the Interaction with Phospholipid Nanodiscs by Millisecond Hydrogen-Deuterium Exchange Mass Spectrometry. 2021 , 32, 1169-1179		2
150	Racemization in Post-Translational Modifications Relevance to Protein Aging, Aggregation and Neurodegeneration: Tip of the Iceberg. 2021 , 13,		1
149	Synucleinopathy-associated pathogenesis in Parkinson's disease and the potential for brain-derived neurotrophic factor. 2021 , 7, 35		7
148	Effects of pH on an IDP conformational ensemble explored by molecular dynamics simulation. <i>Biophysical Chemistry</i> , 2021 , 271, 106552	3.5	6

147	Identification of Two Novel Peptides That Inhibit β Synuclein Toxicity and Aggregation. 2021 , 14, 659926	1
146	Brazilin Removes Toxic Alpha-Synuclein and Seeding Competent Assemblies from Parkinson Brain by Altering Conformational Equilibrium. 2021 , 433, 166878	3
145	Flavonoids, the Family of Plant-derived Antioxidants making inroads into Novel Therapeutic Design against IR-induced Oxidative Stress in Parkinson's Disease. 2021 ,	0
144	Charge Regulation during Amyloid Formation of β Synuclein. 2021 , 143, 7777-7791	10
143	Na leak-current channel (NALCN) at the junction of motor and neuropsychiatric symptoms in Parkinson's disease. 2021 , 128, 749-762	3
142	Multifaceted Therapy of Nanocatalysts in Neurological Diseases. 2021 , 17, 711-743	2
141	A Time-Resolved Diffusion Technique for Detection of the Conformational Changes and Molecular Assembly/Disassembly Processes of Biomolecules. 2021 , 12, 691010	0
140	The Air We Breathe: Air Pollution as a Prevalent Proinflammatory Stimulus Contributing to Neurodegeneration. 2021 , 15, 647643	6
139	Changes in the Mitochondrial Subproteome of Mouse Brain Rpn13-Binding Proteins Induced by the Neurotoxin MPTP and the Neuroprotector Isatin. 2021 , 15, 199-214	
138	The neuroprotective attribution of <i>Ocimum basilicum</i> : a review on the prevention and management of neurodegenerative disorders. 2021 , 7,	1
137	Structures of Pathological and Functional Amyloids and Prions, a Solid-State NMR Perspective. 2021 , 14, 670513	8
136	Modulation of the Interactions Between β Synuclein and Lipid Membranes by Post-translational Modifications. 2021 , 12, 661117	2
135	Alpha-Synuclein as a Biomarker of Parkinson's Disease: Good, but Not Good Enough. 2021 , 13, 702639	12
134	Pursuing Multiple Biomarkers for Early Idiopathic Parkinson's Disease Diagnosis. 2021 , 58, 5517-5532	1
133	Fluorescence Depolarization Kinetics Captures Short-Range Backbone Dihedral Rotations and Long-Range Correlated Dynamics of an Intrinsically Disordered Protein. 2021 , 125, 9708-9718	1
132	C-terminal truncation of β Synuclein alters DNA structure from extension to compaction. 2021 , 568, 43-47	1
131	Structural and Functional Insights into β Synuclein Fibril Polymorphism. 2021 , 11,	6
130	Living with the enemy: from protein-misfolding pathologies we know, to those we want to know. 2021 , 70, 101391	7

129	Heat Shock Protein 70 as a Sex-Skewed Regulator of β Synucleinopathy. 2021 , 1	0
128	Development of β Synuclein Real-Time Quaking-Induced Conversion as a Diagnostic Method for β Synucleinopathies. 2021 , 13, 703984	2
127	Memantine exerts neuroprotective effects by modulating β Synuclein transmission in a parkinsonian model. 2021 , 344, 113810	0
126	Nanodiagnosics: A review of the medical capabilities of nanopores. 2021 , 37, 102425	2
125	Inhibition of alpha-synuclein aggregation by AM17, a synthetic resveratrol derivative. 2021 , 574, 85-90	0
124	Superparamagnetic nanoarchitectures: Multimodal functionalities and applications. 2021 , 538, 168300	5
123	Identification of new alpha-synuclein fibrillogenesis inhibitor using in silico structure-based virtual screening. 2021 , 108, 108010	1
122	Therapeutic potential of <i>Nigella sativa</i> in the prevention of aggregation and glycation of proteins. 2022 , 313-336	
121	Species-barrier on the cross-species oral transmission of bovine AA amyloidosis in mice. 2021 , 83, 962-967	0
120	The food additive fast green FCF inhibits β Synuclein aggregation, disassembles mature fibrils and protects against amyloid-induced neurotoxicity. 2021 , 12, 5465-5477	1
119	Time-resolved detection of SDS-induced conformational changes in β Synuclein by a micro-stopped-flow system.. 2020 , 11, 1086-1097	4
118	Alpha-Synuclein: Biomarker for Parkinson's Disease, Its Estimation Methods, and Targeted Medicinal Therapies. 2021 , 227-248	
117	LncRNA XIST sponges miR-199a-3p to modulate the Sp1/LRRK2 signal pathway to accelerate Parkinson's disease progression. 2021 , 13, 4115-4137	6
116	Neurodegenerative Aspects of Multiple System Atrophy. 2014 , 2157-2180	2
115	Using Probabilistic Strategies to Formalize and Compare β Synuclein Aggregation and Propagation under Different Scenarios. 2013 , 92-105	1
114	CHAPTER 8:Synuclein and Parkinson's Disease: An Update. 2013 , 175-216	6
113	Interaction of β Synuclein and Parkin in iron toxicity on SH-SY5Y cells: implications in the pathogenesis of Parkinson's disease. 2020 , 477, 1109-1122	17
112	Nanotheranostic agents for neurodegenerative diseases. 2020 , 4, 645-675	1

111	Poly (ADP-ribose) induces β synuclein aggregation in neuronal-like cells and interacts with phosphorylated β synuclein in post mortem PD samples.		2
110	High Content Screening and Proteomic Analysis Identify a Kinase Inhibitor that rescues pathological phenotypes in a Patient-Derived Model of Parkinson's Disease.		2
109	Liquid-liquid phase separation and liquid-to-solid transition mediate β synuclein amyloid fibril containing hydrogel formation.		10
108	Proteomic profiling of mitochondria: what does it tell us about the ageing brain?. 2016 , 8, 3161-3179		16
107	Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century. 2013 , 11, 338-78		313
106	1,5-Benzodiazepin-2(3H)-ones: In Vitro Evaluation as Antiparkinsonian Agents. <i>Antioxidants</i> , 2021 , 10,	7.1	0
105	Crocin Inhibits the Fibrillation of Human β synuclein and Disassembles Mature Fibrils: Experimental Findings and Mechanistic Insights from Molecular Dynamics Simulation. <i>ACS Chemical Neuroscience</i> , 2021 , 12, 4037-4057	5.7	2
104	Identification of an optimal foldability criterion to design misfolding resistant protein. 2021 , 155, 144102		0
103	Tryptophan-cardanol fluorescent nanoparticles inhibit β synuclein aggregation and disrupt amyloid fibrils. 2021 , e3374		
102	Accumulating Evidence Suggests that Parkinson's Disease Is a Prion-Like Disorder. 2013 , 97-113		
101	Detecting the Common Biomarkers for Early Stage Parkinson's Disease and Early Stage Alzheimer's Disease Associated with Intrinsically Disordered Protein. 2018 , 25-34		
100	Oligomeric β synuclein-specific degradation by HtrA2/Omi to bestow a neuroprotective function.		
99	Parkinson's Disease. 2019 , 252-273		
98	Mitochondrial Dysfunction in Aging and Neurodegeneration. 2019 , 76-101		
97	Dysregulation of Heat Shock Proteins in Neurodegenerative Diseases: Restorative Roles of Small Molecules and Natural Compounds. 2019 , 85-114		1
96	To target Tau pathologies, we must embrace and reconstruct their complexities. 2021 , 161, 105536		3
95	Vitamin D Inhibits the Early Aggregation of β synuclein and Modulates Exocytosis Revealed by Electrochemical Measurements.		
94	Vitamin D Inhibits the Early Aggregation of β synuclein and Modulates Exocytosis Revealed by Electrochemical Measurements. 2021 , 61, e202111853		1

93	Anti-amyloidogenic effect of artemin on β synuclein. 2020 , 401, 1143-1151		2
92	Brazilin Removes Toxic alpha-Synuclein and Seeding Competent Assemblies from Parkinson Brain by Altering Conformational Equilibrium.		
91	Conformational dynamics of β synuclein during the interaction with phospholipid nanodiscs by Millisecond Hydrogen Deuterium Exchange Mass Spectrometry.		
90	Theoretical Approaches to Lentiviral Mediated Neurotrophin Delivery in Potential Treatments of Parkinson's Disease. 2016 , 89, 215-25		1
89	Role of melatonin in TLR4-mediated inflammatory pathway in the MPTP-induced mouse model. 2021 , 88, 168-177		1
88	DA-9805 protects dopaminergic neurons from endoplasmic reticulum stress and inflammation. 2021 , 145, 112389		0
87	Missense Mutations Modify the Conformational Ensemble of the β -Synuclein Monomer Which Exhibits a Two-Phase Characteristic.. <i>Frontiers in Molecular Biosciences</i> , 2021 , 8, 786123	5.6	1
86	The Interplay of the Unfolded Protein Response in Neurodegenerative Diseases: A Therapeutic Role of Curcumin. 2021 , 13, 767493		1
85	(De)stabilization of Alpha-Synuclein Fibrillary Aggregation by Charged and Uncharged Surfactants. 2021 , 22,		0
84	Polyphenols and Stem Cells for Neuroregeneration in Parkinson's Disease and Amyotrophic Lateral Sclerosis. 2021 ,		
83	Protein Misfolding and Aggregation: The Relatedness between Parkinson's Disease and Hepatic Endoplasmic Reticulum Storage Disorders. 2021 , 22,		2
82	T cells, β synuclein and Parkinson disease.. 2022 , 184, 439-455		0
81	Age-dependent aggregation of β synuclein in the nervous system of gut-brain axis is associated with caspase-1 activation.. 2022 , 1		0
80	Therapeutics in the Pipeline Targeting β -Synuclein for Parkinson's Disease.. 2022 , 74, 207-237		8
79	Sunset Yellow Dye Induces Amorphous Aggregation in β -Lactoglobulin at Acidic pH: A Multi-Techniques Approach.. 2022 , 14,		0
78	Gaucher disease - more than just a rare lipid storage disease.. 2022 , 1		1
77	Aptamers targeting amyloidogenic proteins and their emerging role in neurodegenerative diseases.. 2021 , 101478		4
76	Retinal Degeneration: A Window to Understand the Origin and Progression of Parkinson's Disease?. 2021 , 15, 799526		0

75	Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers.. <i>Movement Disorders</i> , 2022 ,	7	1
74	High content screening and proteomic analysis identify a kinase inhibitor that rescues pathological phenotypes in a patient-derived model of Parkinson's disease.. 2022 , 8, 15		1
73	Local structural dynamics of alpha-synuclein correlate with aggregation in different physiological conditions.		1
72	The gut metabolite, trimethylamine N-oxide inhibits protein folding by affecting cis-trans isomerization and induces cell cycle arrest.. 2021 , 79, 12		1
71	Mitochondrial dysfunction in protein conformational disorders. <i>Journal of Genetics</i> , 2018 , 97, 703-713	1.2	1
70	Pathways to neurodegeneration: lessons learnt from unbiased genetic screens in. <i>Journal of Genetics</i> , 2018 , 97, 773-781	1.2	2
69	Immunotherapeutic interventions in Parkinson's disease: Focus on β Synuclein.. <i>Advances in Protein Chemistry and Structural Biology</i> , 2022 , 129, 381-433	5.3	0
68	Conformational Ensemble of Monomeric β Synuclein in Aqueous and Crowded Environments as revealed by Markov State Model.		
67	-Acetyl-Cysteine: Modulating the Cysteine Redox Proteome in Neurodegenerative Diseases.. <i>Antioxidants</i> , 2022 , 11,	7.1	3
66	Pharmacological Intervention Targeting FAF1 Restores Autophagic Flux for β Synuclein Degradation in the Brain of a Parkinson's Disease Mouse Model.. <i>ACS Chemical Neuroscience</i> , 2022 ,	5.7	
65	Microstructural Organization in β Synuclein Solutions. <i>Macromolecules</i> ,	5.5	4
64	Phenylalanine and indole effects on the pathogenicity of human lysozyme amorphous aggregates.. <i>Enzyme and Microbial Technology</i> , 2022 , 158, 110036	3.8	
63	β Synuclein in Parkinson's disease and advances in detection.. <i>Clinica Chimica Acta</i> , 2022 , 529, 76-86	6.2	1
62	In vitro and in vivo NMR based metabolomics in Parkinson's disease. <i>Journal of Magnetic Resonance Open</i> , 2022 , 10-11, 100050	0.4	1
61	The Myelin-Weighted Connectome in Parkinson's Disease.. <i>Movement Disorders</i> , 2021 ,	7	1
60	Parkinson's Disease and the Metal-Microbiome-Gut-Brain Axis: A Systems Toxicology Approach.. <i>Antioxidants</i> , 2021 , 11,	7.1	0
59	Structural and mechanistic insights into modulation of β Synuclein fibril formation by aloin and emodin.. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2022 , 130151	4	0
58	Image_1.JPEG. 2019 ,		

57	Image_2.JPEG. 2019 ,		
56	Image_3.JPEG. 2019 ,		
55	Image_4.JPEG. 2019 ,		
54	Presentation_1.pdf. 2020 ,		
53	Aptamers Targeting Hallmark Proteins of Neurodegeneration.. <i>Nucleic Acid Therapeutics</i> , 2022 ,	4.8	0
52	Mitochondrial Dysfunction in Aging and Neurodegeneration. 2022 , 253-278		
51	Second Sphere Interactions in Amyloidogenic Diseases.. <i>Chemical Reviews</i> , 2022 ,	68.1	3
50	Role of Environmental Toxicants on Neurodegenerative Disorders. <i>Frontiers in Toxicology</i> , 2022 , 4,	1.6	3
49	Aggregation of a Parkinson's Disease-Related Peptide: When Does Urea Weaken Hydrophobic Interactions?. <i>ACS Chemical Neuroscience</i> ,	5.7	
48	Lipid membrane-mediated assembly of the functional amyloid-forming peptide Somatostatin-14. <i>Biophysical Chemistry</i> , 2022 , 106830	3.5	0
47	Alpha-Synuclein Aggregation Pathway in Parkinson's Disease: Current Status and Novel Therapeutic Approaches. <i>Cells</i> , 2022 , 11, 1732	7.9	3
46	Determine both the conformation and orientation of a specific residue in β synuclein(61-95) even in monolayer by ^{13}C isotopic label and p-polarized multiple-angle incidence resolution spectrometry (pMAIRS). <i>Analytical Sciences</i> ,	1.7	
45	Wide-Line NMR Melting Diagrams, Their Thermodynamic Interpretation, and Secondary Structure Predictions for A30P and E46K β Synuclein. <i>ACS Omega</i> ,	3.9	
44	Plasticity of Membrane Binding by the Central Region of β Synuclein. <i>Frontiers in Molecular Biosciences</i> , 9,	5.6	1
43	Dynamical Behavior of Disordered Regions in Disease-Related Proteins Revealed by Quasielastic Neutron Scattering. <i>Medicina (Lithuania)</i> , 2022 , 58, 795	3.1	0
42	Wild-Type β Synuclein and Variants Occur in Different Disordered Dimers and Pre-Fibrillar Conformations in Early Stage of Aggregation. <i>Frontiers in Molecular Biosciences</i> , 9,	5.6	2
41	Zinc ions prevent β Synuclein aggregation by enhancing chaperone function of human serum albumin.		
40	Deciphering Intertwined Molecular Pathways Underlying Metabolic Syndrome Leading to Parkinson's Disease. <i>ACS Chemical Neuroscience</i> ,	5.7	

- 39 Aberrant liquid-liquid phase separation and amyloid aggregation of proteins related to neurodegenerative diseases. **2022**, 220, 703-720 0
- 38 Molecular dynamics simulations of an β -Synuclein NAC domain fragment with a ff14IDPSFF IDP-specific force field suggest β -sheet intermediate states of fibrillation. **2022**, 24, 18841-18853 1
- 37 Interaction of membrane vesicles with the Pseudomonas functional amyloid protein FapC facilitates amyloid formation. **2022**, 2, 100055 0
- 36 Small soluble β -Synuclein aggregates are the toxic species in Parkinson's disease. **2022**, 13, 2
- 35 Characterization of exogenous SN response genes and their relation to Parkinson's disease using network analyses. 13, 0
- 34 Liquid-Liquid Phase Separation Promotes Protein Aggregation and Its Implications in Ferroptosis in Parkinson's Disease Dementia. **2022**, 2022, 1-13 1
- 33 Effects of radiation exposure on brain health: a state of the art and new challenges. 0
- 32 Nanomedicine in the Face of Parkinson's Disease: From Drug Delivery Systems to Nanozymes. **2022**, 11, 3445 0
- 31 Cellular Models of Alpha-Synuclein Aggregation: What Have We Learned and Implications for Future Study. **2022**, 10, 2649 0
- 30 Zinc ions prevent β -Synuclein aggregation by enhancing chaperone function of human serum albumin. **2022**, 0
- 29 Gastric Enteric Glial Cells: A New Contributor to the Synucleinopathies in the MPTP-Induced Parkinsonism Mouse. **2022**, 27, 7414 0
- 28 Tuning the surface charge of phospholipid bilayers inhibits insulin fibrilization. **2022**, 220, 112904 0
- 27 Inhibition of β -Synuclein fibrillation by natural polyphenols: Thermodynamic and biophysical aspects. **2023**, 177, 106951 0
- 26 How important is the N-terminal acetylation of alpha-synuclein for its function and aggregation into amyloids?. 16, 1
- 25 Protein misfolding and related human diseases: A comprehensive review of toxicity, proteins involved, and current therapeutic strategies. **2022**, 223, 143-160 0
- 24 HtrA2 regulates β -Synuclein-mediated mitochondrial reactive oxygen species production in the mitochondria of microglia. **2022**, 0
- 23 How binding to surfaces affects disorder?. **2023**, 455-489 0
- 22 Review on the interactions between dopamine metabolites and β -Synuclein in causing Parkinson's disease. **2023**, 162, 105461 0

- 21 Pyrogallol, Corilagin and Chebulagic acid target the fuzzy coat of alpha-synuclein to inhibit the fibrillization of the protein. **2022**, 12, 35770-35777 ○
- 20 Millisecond Hydrogen/Deuterium-Exchange Mass Spectrometry Approach to Correlate Local Structure and Aggregation in β Synuclein. **2022**, 94, 16711-16719 2
- 19 S-nitrosylated PARIS Leads to the Sequestration of PGC-1 β into Insoluble Deposits in Parkinson Disease Model. **2022**, 11, 3682 ○
- 18 From lysosomal storage disorders to Parkinson Disease [Challenges and opportunities. **2022**, 167932 ○
- 17 Simultaneous Determination of Size and Shape of Single β Synuclein Oligomers in Solution. ○
- 16 Human mini-brains for reconstituting central nervous system disorders. ○
- 15 Alpha-synuclein: a pathological factor with A β and tau and biomarker in Alzheimer disease. **2022**, 14, ○
- 14 m⁶A mRNA methylation in human brain is disrupted in Lewy body disorders. ○
- 13 The KEAP1-NRF2 system and neurodegenerative diseases. ○
- 12 Functionally active cross-linked protein oligomers formed by homocysteine thiolactone. **2023**, 13, ○
- 11 Neurodegenerative Aspects of Multiple System Atrophy. **2022**, 1869-1892 ○
- 10 PPARs and Their Neuroprotective Effects in Parkinson Disease: A Novel Therapeutic Approach in β Synucleinopathy?. **2023**, 24, 3264 ○
- 9 DEVELOPMENT OF MURINE STEM CELLS WITH CONDITIONAL KNOCKOUT OF HUMANIZED SNCA GENE. **2023**, 10, 525-535 ○
- 8 Neurotrophin mimetics and tropomyosin kinase receptors: a futuristic pharmacological tool for Parkinson. ○
- 7 Fuzzy Drug Targets: Disordered Proteins in the Drug-Discovery Realm. **2023**, 8, 9729-9747 ○
- 6 Morphology-Dependent Interactions between β Synuclein Monomers and Fibrils. **2023**, 24, 5191 ○
- 5 The KEAP1-NRF2 System and Neurodegenerative Diseases. ○
- 4 The Anthocyanidin Peonidin Interferes with an Early Step in the Fibrillation Pathway of β Synuclein and Modulates It toward Amorphous Aggregates. ○

- 3 Artificial intelligence in precision medicine. **2023**, 531-569
- 2 α -Synuclein Structural Diversity and the Cellular Environment in α -Synuclein Transmission Models and Humans. **2023**, 20, 67-82
- 1 Disease association and comparative genomics of compositional bias in human proteins. 12, 198